Oral drug dosing following bariatric surgery: General concepts and specific dosing advice

Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of clinical pharmacology 2021-12, Vol.87 (12), p.4560-4576
Hauptverfasser: Kingma, Jurjen S., Burgers, Desirée M. T., Monpellier, Valerie M., Wiezer, Marinus J., Blussé van Oud‐Alblas, Heleen J., Vaughns, Janelle D., Sherwin, Catherine M. T., Knibbe, Catherijne A. J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4576
container_issue 12
container_start_page 4560
container_title British journal of clinical pharmacology
container_volume 87
creator Kingma, Jurjen S.
Burgers, Desirée M. T.
Monpellier, Valerie M.
Wiezer, Marinus J.
Blussé van Oud‐Alblas, Heleen J.
Vaughns, Janelle D.
Sherwin, Catherine M. T.
Knibbe, Catherijne A. J.
description Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation, and decreased gastrointestinal transit time may be expected. In the years after bariatric surgery, patients will also substantially lose weight. As a result of these changes, the absorption, distribution, metabolism and/or elimination of drugs may be altered. The purpose of this article is to report the general influence of bariatric surgery on oral drug absorption, and to provide guidance for dosing of commonly used drugs in this special population. Upon oral drug administration, the time to maximum concentration is often earlier and this concentration may be higher with less consistent effects on trough concentrations and exposure. Additionally, prescription of liquid formulations to bariatric patients is supported by some reports, even though the high sugar load of these suspensions may be of concern. Studies on extended‐release medications result in an unaltered exposure for a substantial number of drugs. Also, studies evaluating the influence of timing after surgery show dynamic absorption profiles. Although for this group specific advice can be proposed for many drugs, we conclude that there is insufficient evidence for general advice for oral drug therapy after bariatric surgery, implying that a risk assessment on a case‐by‐case basis is required for each drug.
doi_str_mv 10.1111/bcp.14913
format Article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9291886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BCP14913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4153-4c4d69d03fb065b99701f937f299f25c772f5b3a4fd188fb5369fbb41e3912783</originalsourceid><addsrcrecordid>eNp1kDtPwzAYRS0EoqUw8AdQVoa0fsRJzYAEFRSkSmWAgcnyMxilSWT3of57XFIqGPBiSz73fJ8uAJcIDlE8I6naIcoYIkegj0hOU4wwPQZ9SGCeUkxRD5yF8AkhIiinp6BHCGOQjVEfvM-9qBLtV2Wim-DqMrFNVTWb3UsK78TSO5WElS-N394kU1ObXUA1tTLtMiSi1klojXI2YnuD0GunzDk4saIK5mJ_D8Db48Pr5CmdzafPk7tZqjJESZqpTOdMQ2IlzKlkrIDIMlJYzJjFVBUFtlQSkVmNxmMrKcmZlTJDhjCEizEZgNvO267kwmhl6mXckLfeLYTf8kY4_vendh-8bNacYRaNeRRcdwLlmxC8sYcsgnzXL4_98u9-I3v1e9iB_Ck0AqMO2LjKbP838fvJS6f8AhSshmU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Oral drug dosing following bariatric surgery: General concepts and specific dosing advice</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kingma, Jurjen S. ; Burgers, Desirée M. T. ; Monpellier, Valerie M. ; Wiezer, Marinus J. ; Blussé van Oud‐Alblas, Heleen J. ; Vaughns, Janelle D. ; Sherwin, Catherine M. T. ; Knibbe, Catherijne A. J.</creator><creatorcontrib>Kingma, Jurjen S. ; Burgers, Desirée M. T. ; Monpellier, Valerie M. ; Wiezer, Marinus J. ; Blussé van Oud‐Alblas, Heleen J. ; Vaughns, Janelle D. ; Sherwin, Catherine M. T. ; Knibbe, Catherijne A. J.</creatorcontrib><description>Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation, and decreased gastrointestinal transit time may be expected. In the years after bariatric surgery, patients will also substantially lose weight. As a result of these changes, the absorption, distribution, metabolism and/or elimination of drugs may be altered. The purpose of this article is to report the general influence of bariatric surgery on oral drug absorption, and to provide guidance for dosing of commonly used drugs in this special population. Upon oral drug administration, the time to maximum concentration is often earlier and this concentration may be higher with less consistent effects on trough concentrations and exposure. Additionally, prescription of liquid formulations to bariatric patients is supported by some reports, even though the high sugar load of these suspensions may be of concern. Studies on extended‐release medications result in an unaltered exposure for a substantial number of drugs. Also, studies evaluating the influence of timing after surgery show dynamic absorption profiles. Although for this group specific advice can be proposed for many drugs, we conclude that there is insufficient evidence for general advice for oral drug therapy after bariatric surgery, implying that a risk assessment on a case‐by‐case basis is required for each drug.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/bcp.14913</identifier><identifier>PMID: 33990981</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Administration, Oral ; Bariatric Surgery - adverse effects ; Bariatric Surgery - methods ; clinical pharmacology ; Drug-Related Side Effects and Adverse Reactions ; Enterohepatic Circulation ; Humans ; Invited Review ; nutrition ; obesity ; Pharmaceutical Preparations - administration &amp; dosage ; pharmacokinetics ; Pharmacology ; surgery ; Weight Loss</subject><ispartof>British journal of clinical pharmacology, 2021-12, Vol.87 (12), p.4560-4576</ispartof><rights>2021 The Authors. published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</rights><rights>2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4153-4c4d69d03fb065b99701f937f299f25c772f5b3a4fd188fb5369fbb41e3912783</citedby><cites>FETCH-LOGICAL-c4153-4c4d69d03fb065b99701f937f299f25c772f5b3a4fd188fb5369fbb41e3912783</cites><orcidid>0000-0002-0844-3207 ; 0000-0001-9893-4415</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbcp.14913$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbcp.14913$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33990981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kingma, Jurjen S.</creatorcontrib><creatorcontrib>Burgers, Desirée M. T.</creatorcontrib><creatorcontrib>Monpellier, Valerie M.</creatorcontrib><creatorcontrib>Wiezer, Marinus J.</creatorcontrib><creatorcontrib>Blussé van Oud‐Alblas, Heleen J.</creatorcontrib><creatorcontrib>Vaughns, Janelle D.</creatorcontrib><creatorcontrib>Sherwin, Catherine M. T.</creatorcontrib><creatorcontrib>Knibbe, Catherijne A. J.</creatorcontrib><title>Oral drug dosing following bariatric surgery: General concepts and specific dosing advice</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation, and decreased gastrointestinal transit time may be expected. In the years after bariatric surgery, patients will also substantially lose weight. As a result of these changes, the absorption, distribution, metabolism and/or elimination of drugs may be altered. The purpose of this article is to report the general influence of bariatric surgery on oral drug absorption, and to provide guidance for dosing of commonly used drugs in this special population. Upon oral drug administration, the time to maximum concentration is often earlier and this concentration may be higher with less consistent effects on trough concentrations and exposure. Additionally, prescription of liquid formulations to bariatric patients is supported by some reports, even though the high sugar load of these suspensions may be of concern. Studies on extended‐release medications result in an unaltered exposure for a substantial number of drugs. Also, studies evaluating the influence of timing after surgery show dynamic absorption profiles. Although for this group specific advice can be proposed for many drugs, we conclude that there is insufficient evidence for general advice for oral drug therapy after bariatric surgery, implying that a risk assessment on a case‐by‐case basis is required for each drug.</description><subject>Administration, Oral</subject><subject>Bariatric Surgery - adverse effects</subject><subject>Bariatric Surgery - methods</subject><subject>clinical pharmacology</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Enterohepatic Circulation</subject><subject>Humans</subject><subject>Invited Review</subject><subject>nutrition</subject><subject>obesity</subject><subject>Pharmaceutical Preparations - administration &amp; dosage</subject><subject>pharmacokinetics</subject><subject>Pharmacology</subject><subject>surgery</subject><subject>Weight Loss</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kDtPwzAYRS0EoqUw8AdQVoa0fsRJzYAEFRSkSmWAgcnyMxilSWT3of57XFIqGPBiSz73fJ8uAJcIDlE8I6naIcoYIkegj0hOU4wwPQZ9SGCeUkxRD5yF8AkhIiinp6BHCGOQjVEfvM-9qBLtV2Wim-DqMrFNVTWb3UsK78TSO5WElS-N394kU1ObXUA1tTLtMiSi1klojXI2YnuD0GunzDk4saIK5mJ_D8Db48Pr5CmdzafPk7tZqjJESZqpTOdMQ2IlzKlkrIDIMlJYzJjFVBUFtlQSkVmNxmMrKcmZlTJDhjCEizEZgNvO267kwmhl6mXckLfeLYTf8kY4_vendh-8bNacYRaNeRRcdwLlmxC8sYcsgnzXL4_98u9-I3v1e9iB_Ck0AqMO2LjKbP838fvJS6f8AhSshmU</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Kingma, Jurjen S.</creator><creator>Burgers, Desirée M. T.</creator><creator>Monpellier, Valerie M.</creator><creator>Wiezer, Marinus J.</creator><creator>Blussé van Oud‐Alblas, Heleen J.</creator><creator>Vaughns, Janelle D.</creator><creator>Sherwin, Catherine M. T.</creator><creator>Knibbe, Catherijne A. J.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0844-3207</orcidid><orcidid>https://orcid.org/0000-0001-9893-4415</orcidid></search><sort><creationdate>202112</creationdate><title>Oral drug dosing following bariatric surgery: General concepts and specific dosing advice</title><author>Kingma, Jurjen S. ; Burgers, Desirée M. T. ; Monpellier, Valerie M. ; Wiezer, Marinus J. ; Blussé van Oud‐Alblas, Heleen J. ; Vaughns, Janelle D. ; Sherwin, Catherine M. T. ; Knibbe, Catherijne A. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4153-4c4d69d03fb065b99701f937f299f25c772f5b3a4fd188fb5369fbb41e3912783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Oral</topic><topic>Bariatric Surgery - adverse effects</topic><topic>Bariatric Surgery - methods</topic><topic>clinical pharmacology</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Enterohepatic Circulation</topic><topic>Humans</topic><topic>Invited Review</topic><topic>nutrition</topic><topic>obesity</topic><topic>Pharmaceutical Preparations - administration &amp; dosage</topic><topic>pharmacokinetics</topic><topic>Pharmacology</topic><topic>surgery</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kingma, Jurjen S.</creatorcontrib><creatorcontrib>Burgers, Desirée M. T.</creatorcontrib><creatorcontrib>Monpellier, Valerie M.</creatorcontrib><creatorcontrib>Wiezer, Marinus J.</creatorcontrib><creatorcontrib>Blussé van Oud‐Alblas, Heleen J.</creatorcontrib><creatorcontrib>Vaughns, Janelle D.</creatorcontrib><creatorcontrib>Sherwin, Catherine M. T.</creatorcontrib><creatorcontrib>Knibbe, Catherijne A. J.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kingma, Jurjen S.</au><au>Burgers, Desirée M. T.</au><au>Monpellier, Valerie M.</au><au>Wiezer, Marinus J.</au><au>Blussé van Oud‐Alblas, Heleen J.</au><au>Vaughns, Janelle D.</au><au>Sherwin, Catherine M. T.</au><au>Knibbe, Catherijne A. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral drug dosing following bariatric surgery: General concepts and specific dosing advice</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>87</volume><issue>12</issue><spage>4560</spage><epage>4576</epage><pages>4560-4576</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><abstract>Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation, and decreased gastrointestinal transit time may be expected. In the years after bariatric surgery, patients will also substantially lose weight. As a result of these changes, the absorption, distribution, metabolism and/or elimination of drugs may be altered. The purpose of this article is to report the general influence of bariatric surgery on oral drug absorption, and to provide guidance for dosing of commonly used drugs in this special population. Upon oral drug administration, the time to maximum concentration is often earlier and this concentration may be higher with less consistent effects on trough concentrations and exposure. Additionally, prescription of liquid formulations to bariatric patients is supported by some reports, even though the high sugar load of these suspensions may be of concern. Studies on extended‐release medications result in an unaltered exposure for a substantial number of drugs. Also, studies evaluating the influence of timing after surgery show dynamic absorption profiles. Although for this group specific advice can be proposed for many drugs, we conclude that there is insufficient evidence for general advice for oral drug therapy after bariatric surgery, implying that a risk assessment on a case‐by‐case basis is required for each drug.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>33990981</pmid><doi>10.1111/bcp.14913</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-0844-3207</orcidid><orcidid>https://orcid.org/0000-0001-9893-4415</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0306-5251
ispartof British journal of clinical pharmacology, 2021-12, Vol.87 (12), p.4560-4576
issn 0306-5251
1365-2125
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9291886
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Administration, Oral
Bariatric Surgery - adverse effects
Bariatric Surgery - methods
clinical pharmacology
Drug-Related Side Effects and Adverse Reactions
Enterohepatic Circulation
Humans
Invited Review
nutrition
obesity
Pharmaceutical Preparations - administration & dosage
pharmacokinetics
Pharmacology
surgery
Weight Loss
title Oral drug dosing following bariatric surgery: General concepts and specific dosing advice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A13%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20drug%20dosing%20following%20bariatric%20surgery:%20General%20concepts%20and%20specific%20dosing%20advice&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Kingma,%20Jurjen%20S.&rft.date=2021-12&rft.volume=87&rft.issue=12&rft.spage=4560&rft.epage=4576&rft.pages=4560-4576&rft.issn=0306-5251&rft.eissn=1365-2125&rft_id=info:doi/10.1111/bcp.14913&rft_dat=%3Cwiley_pubme%3EBCP14913%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33990981&rfr_iscdi=true